Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Ear and labyrinth disorders – page 3

  • 37 clinical trials
  • 14 recruiting
  • 43 conditions
  • 18 countries

Conditions in this area

43 conditions with trials, the busiest first

Deafness8Alport's syndrome6Paraganglion neoplasm5Deafness neurosensory4Phaeochromocytoma4Otitis media3Vestibular disorder3Focal segmental glomerulosclerosis2Meniere's disease2Neuroendocrine tumour2Tinnitus2Usher's syndrome2Wolfram syndrome2Acoustic neuroma1Bile duct cancer1Chronic kidney disease1Chronic rhinosinusitis with nasal polyps1Colorectal cancer1Deafness bilateral1Deafness traumatic1Dizziness1Ductal adenocarcinoma of pancreas1Ear discomfort1Endolymphatic hydrops1+19

Clinical trials in Ear and labyrinth disorders

37 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

37 clinical trials

Alport's syndrome

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Vonafexor
  • Sponsor:ENYO Pharma

Deafness

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:R-Azasetron Besilate
  • Sponsor:Sensorion

Usher's syndrome

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lentiviral Vector Derived From The Equine Infectious Anaemia Virus Containing The Human Myo7A Gene
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acoustic neuroma

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Retinitis pigmentosa+1

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Aavantgarde Bio S.r.l.

Wolfram syndrome

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Valproate
  • Sponsor:Centre D'Etude Des Cellules Souches

Focal segmental glomerulosclerosis+1

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01
  • Sponsor:River 3 Renal Corp.

Paraganglion neoplasm+3

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:L-Arginine Hydrochloride
  • Sponsor:Advanced Accelerator Applications

Deafness neurosensory

Not recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AudioCure Pharma GmbH

Deafness neurosensory

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Acou085
  • Sponsor:Acousia Therapeutics GmbH

Alport's syndrome

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Setanaxib
  • Sponsor:Calliditas Therapeutics Suisse S.A.

Deafness bilateral

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Sensorion

Substances studied in this area

The therapies tested most often in Ear and labyrinth disorders trials.

Prednisolone3 clinical trialsAavanc80-3'Hotof2 clinical trialsAavanc80-5'Hotof2 clinical trialsOxygen2 clinical trialsPlacebo2 clinical trialsSodium Chloride2 clinical trialsTriamcinolone Acetonide2 clinical trials6-Fluoro-9-Methyl-9H-Pyrido[3,4-B]-Indole1 clinical trialAbiraterone Acetate1 clinical trial
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.